Recent Cases
4 November 2009 - Acino acquires Iclaprim business from Arpida
Acino Holding Ltd. acquires from Arpida Ltd., a pharmaceutical company domiciled in Reinach, all assets, data and intellectual property rights pertaining to the antibiotic Iclaprim. The Acino Group specializes in the development, registration and manufacture of generic and innovative pharmaceuticals and is headquartered in Basel. Acino Holding Ltd. is listed on the SIX Swiss Exchange. The transaction is subject to approval by Arpida shareholders at the extraordinary general meeting on 26 November 2009.
Acino was advised by Bär & Karrer AG. The team included Thomas U. Reutter, Markus Wang (IP) and Daniel Raun.